Stephen Frank Mahoney
Chief Executive Officer bij VIRIDIAN THERAPEUTICS, INC.
Vermogen: 32 370 $ op 31-03-2024
Profiel
Stephen Frank Mahoney is the founder of Kiniksa Pharmaceuticals Ltd., which was founded in 2015.
He held the title of President & Chief Operating Officer from 2017 to 2019.
He is currently the President, Chief Executive Officer & Director at Viridian Therapeutics, Inc. since 2023.
He is also a Director at Vesselon, Inc. His former positions include Regional Legal Director at Genzyme Corp.
from 2003 to 2012, Attorney at Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC, Chief Commercial Officer & Senior Vice President at Synageva BioPharma Corp.
from 2014 to 2015, COO, CFO, Treasurer & Chief Accounting Officer at Magenta Therapeutics, Inc. from 2020 to 2023, Chief Operating & Financial Officer at Dianthus Therapeutics, Inc. from 2020 to 2023, and Attorney at Genzyme Corp.
He has an undergraduate degree from The Colorado College, a graduate degree from Boston College Law School, and an MBA from Wallace E Carroll School of Management.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 31-03-2023 | 1 079 ( 0.00% ) | 32 370 $ | 31-03-2024 |
Actieve functies van Stephen Frank Mahoney
| Bedrijven | Functie | Begin |
|---|---|---|
| VIRIDIAN THERAPEUTICS, INC. | Chief Executive Officer | 30-10-2023 |
Vesselon, Inc.
 Vesselon, Inc. Medical SpecialtiesHealth Technology Vesselon, Inc. develops a portable ultrasound medical device for treating neurodegenerative diseases and brain & ischemic strokes. It commercializes a drug delivery platform that combines ultrasound and microbubbles to deliver the drugs across tissue barriers directly into a target without the need to modify the drug through a process, microbubble assisted sono-therapy. The company was founded by Clayton T. Larsen and Rhodemann Li in 2012 and is headquartered in Norwalk, CT. | Director/Board Member | - |
Eerdere bekende functies van Stephen Frank Mahoney
| Bedrijven | Functie | Einde |
|---|---|---|
| DIANTHUS THERAPEUTICS, INC. | Director of Finance/CFO | 01-09-2023 |
| KINIKSA PHARMACEUTICALS, LTD. | Founder | 15-11-2019 |
| SYNAGEVA BIOPHARMA CORP | Corporate Officer/Principal | 01-01-2015 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
| MAGENTA THERAPEUTICS | Director of Finance/CFO | - |
Opleiding van Stephen Frank Mahoney
| The Colorado College | Undergraduate Degree |
| Boston College Law School | Graduate Degree |
| Wallace E Carroll School of Management | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| KINIKSA PHARMACEUTICALS, LTD. | Health Technology |
| VIRIDIAN THERAPEUTICS, INC. | Health Technology |
| DIANTHUS THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Vesselon, Inc.
Vesselon, Inc. Medical SpecialtiesHealth Technology Vesselon, Inc. develops a portable ultrasound medical device for treating neurodegenerative diseases and brain & ischemic strokes. It commercializes a drug delivery platform that combines ultrasound and microbubbles to deliver the drugs across tissue barriers directly into a target without the need to modify the drug through a process, microbubble assisted sono-therapy. The company was founded by Clayton T. Larsen and Rhodemann Li in 2012 and is headquartered in Norwalk, CT. | Health Technology |
Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC
 Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC Miscellaneous Commercial ServicesCommercial Services Mintz, Levin, Cohn, Ferris, Glovsky & Popeo PC provides legal services. The firm offers services to the communications, education, environmental, health, immigration, public finance, real estate and tax industries. The company was founded in 1933 and is headquartered in Boston, MA. | Commercial Services |
Synageva BioPharma Corp.
 Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
